MedTrace Logo

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

NCT04975061 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2021-07-23

No results posted yet for this study

Summary

This study is a single-arm, open, multi-center phase II clinical trial, the main purpose of which is to evaluate the effectiveness and safety of YY-20394 in the treatment of patients with relapsed/refractory thymic cancer.

The research adopts the Simon two-stage design method, which is carried out in two stages.

Conditions

  • Effectiveness，Safety，Thymic Cancer

Interventions

DRUG

YY-20394

YY-20394 is a small molecule inhibitor.

Sponsors & Collaborators

  • Shanghai YingLi Pharmaceutical Co. Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-12-01
Completion
2022-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975061 on ClinicalTrials.gov